A Phase II Study Of OSI-774 [erlotinib] In Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 23 Jan 2013 Primary endpoint amended as reported by ClinicalTrials.gov.
- 23 Jan 2013 Actual end date added 1 May 2007 as reported by ClinicalTrials.gov.
- 08 May 2007 Status changed from in progress to completed